Cutler Group LP Tcr2 Therapeutics Inc. Put Options Transaction History

Cutler Group LP

  • $307 Million
  • Q1 2024

Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2020

Oct 27, 2020
BUY
$13.1 - $20.69 $11,790 - $18,621
900 Added 900.0%
1,000 $0
Q2 2020

Jul 22, 2020
BUY
$6.51 - $16.85 $651 - $1,685
100 New
100 $0

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email